Results 101 to 110 of about 2,932,876 (332)
Association of Special Libraries and Information Bureaux: Annual Report [PDF]
, 1940 openalex +1 more source
Molecular Oncology, EarlyView.This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima +6 more
wiley +1 more source
027.7, 2014 The Consortium of European Research Libraries (CERL, http://www.cerl.org) is a membership organisation, involving an active community of c. 190 libraries each with a keen focus on cultural heritage in the form of early printed books and manuscripts ...
Ingeborg Versprille +2 more
doaj +1 more source
Molecular Oncology, EarlyView.Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li +12 more
wiley +1 more source
Special Libraries, November 1932 [PDF]
, 1932 Volume 23, Issue 8https://scholarworks.sjsu.edu/sla_sl_1932/1007/thumbnail ...
Special Libraries Association
core +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Special Libraries, February 1910 [PDF]
, 1910 Volume 1, Issue 2https://scholarworks.sjsu.edu/sla_sl_1910/1001/thumbnail ...
Special Libraries Association
core +1 more source
Catalogue of Lewis' Medical and Scientific Library Revised to the end of 1937. Part I. Authors and Titles [PDF]
, 1940 openalex +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source